Adavosertib has demonstrated potent inhibition of cell survival, growth, and proliferation in TP53 mutant non-small cell lung cancer models, consistent with synthetic lethality between WEE1 inhibition and p53 loss [180]. Here, TP53 is linked to non-small cell lung carcinoma.